Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Protection | 1 | 2023 | 26 | 0.890 |
Why?
|
| Radiation Exposure | 1 | 2023 | 25 | 0.890 |
Why?
|
| Cardiovascular Diseases | 6 | 2019 | 714 | 0.860 |
Why?
|
| Atherosclerosis | 2 | 2018 | 257 | 0.610 |
Why?
|
| Arteries | 1 | 2018 | 180 | 0.570 |
Why?
|
| Immunologic Factors | 1 | 2018 | 172 | 0.560 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 168 | 0.550 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 345 | 0.510 |
Why?
|
| Cytokines | 1 | 2018 | 805 | 0.470 |
Why?
|
| Immunotherapy | 1 | 2018 | 693 | 0.410 |
Why?
|
| Health Promotion | 2 | 2018 | 165 | 0.250 |
Why?
|
| X-Rays | 1 | 2023 | 135 | 0.220 |
Why?
|
| Catheters | 1 | 2024 | 76 | 0.220 |
Why?
|
| Heart Valve Diseases | 1 | 2024 | 115 | 0.210 |
Why?
|
| Cardiac Catheterization | 1 | 2023 | 303 | 0.200 |
Why?
|
| Risk Reduction Behavior | 2 | 2018 | 97 | 0.180 |
Why?
|
| Risk Factors | 7 | 2019 | 5522 | 0.180 |
Why?
|
| Life Style | 2 | 2018 | 173 | 0.170 |
Why?
|
| Comorbidity | 3 | 2018 | 951 | 0.170 |
Why?
|
| Marital Status | 1 | 2019 | 42 | 0.170 |
Why?
|
| Cardiac Rehabilitation | 1 | 2018 | 5 | 0.160 |
Why?
|
| Protective Factors | 1 | 2018 | 23 | 0.160 |
Why?
|
| Troponin I | 1 | 2018 | 26 | 0.150 |
Why?
|
| Myocardial Revascularization | 1 | 2018 | 30 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 102 | 0.150 |
Why?
|
| Preventive Health Services | 1 | 2018 | 39 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2019 | 2309 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 59 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2018 | 158 | 0.150 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2018 | 60 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 52 | 0.150 |
Why?
|
| Mortality | 1 | 2018 | 149 | 0.140 |
Why?
|
| Primary Prevention | 1 | 2017 | 82 | 0.140 |
Why?
|
| Women's Health | 1 | 2017 | 102 | 0.140 |
Why?
|
| Prognosis | 3 | 2019 | 3802 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 434 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2017 | 191 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 220 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 375 | 0.120 |
Why?
|
| Humans | 13 | 2024 | 89760 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2023 | 8283 | 0.120 |
Why?
|
| Biomarkers | 2 | 2017 | 1771 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 1728 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 364 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 426 | 0.100 |
Why?
|
| Anthracyclines | 1 | 2012 | 38 | 0.100 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2011 | 32 | 0.090 |
Why?
|
| Ureteroscopy | 1 | 2011 | 38 | 0.090 |
Why?
|
| Lithotripsy | 1 | 2011 | 44 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 1676 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2012 | 265 | 0.080 |
Why?
|
| Heart | 1 | 2012 | 574 | 0.080 |
Why?
|
| Pancreas | 1 | 2011 | 249 | 0.080 |
Why?
|
| United States | 2 | 2018 | 7037 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 1201 | 0.080 |
Why?
|
| Kidney Calculi | 1 | 2011 | 343 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2018 | 3400 | 0.070 |
Why?
|
| Sex Factors | 2 | 2019 | 1070 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1793 | 0.060 |
Why?
|
| Echocardiography | 2 | 2024 | 938 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 2416 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2019 | 97 | 0.040 |
Why?
|
| Animals | 1 | 2018 | 27456 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 168 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 3019 | 0.040 |
Why?
|
| Models, Organizational | 1 | 2018 | 47 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 54 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 270 | 0.030 |
Why?
|
| Global Health | 1 | 2018 | 192 | 0.030 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2015 | 41 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 856 | 0.030 |
Why?
|
| Female | 5 | 2019 | 46439 | 0.030 |
Why?
|
| Androgens | 1 | 2015 | 177 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 157 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 201 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1535 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2015 | 159 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2015 | 154 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 234 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 6847 | 0.030 |
Why?
|
| Male | 4 | 2019 | 42632 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1864 | 0.030 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2012 | 8 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2015 | 255 | 0.030 |
Why?
|
| Diet | 1 | 2015 | 443 | 0.030 |
Why?
|
| Exercise | 1 | 2015 | 325 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2012 | 74 | 0.030 |
Why?
|
| Amylases | 1 | 2011 | 14 | 0.020 |
Why?
|
| Lipase | 1 | 2011 | 21 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2012 | 248 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 3030 | 0.020 |
Why?
|
| Hypertension | 1 | 2015 | 747 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 743 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 19280 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 972 | 0.020 |
Why?
|
| Middle Aged | 2 | 2018 | 26129 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 4328 | 0.010 |
Why?
|
| Adult | 2 | 2012 | 26742 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 5346 | 0.010 |
Why?
|